<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>SARS-CoV-2 Study</title>

  <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;600;700&display=swap&quot; rel="font" />

  <style>
    body {
      font-family: 'Montserrat', sans-serif;
      max-width: 900px;
      margin: 40px auto;
      padding: 0 20px;
      line-height: 1.6;
      color: rgb(34, 34, 34);
    }

    .header {
      font-size: 13px;
      font-weight: 600;
      text-transform: uppercase;
      color: rgb(204, 51, 0);
    }

    .label {
      color: rgb(85, 85, 85);
      margin-left: 10px;
    }
    .label .free {
    color: rgba(69, 4, 102, 0.878);
    font-weight: 600;    
    }

    h1 {
      font-family: Georgia, 'Times New Roman', Times, serif;
      font-size: 26px;
      margin: 20px 0 10px;
    }

    h2 {
      font-family: Georgia, 'Times New Roman', Times, serif;
      font-size: 18px;
      color: rgb(102, 102, 102);
      font-weight: 500;
      margin-top: 0;
    }

    .image {
      float: right;
      margin-left: 20px;
      width: 260px;
    }

    .image img {
      width: 70%;
      height: 150px;
    }

    .article-body {
      font-family: Georgia, 'Times New Roman', Times, serif;
      font-size: 16px;
      margin-top: 20px;
    }

    .correction {
      margin-top: 25px;
      font-weight: 600;
      font-size: 16px;
    }
    .correction strong {
     color: rgb(0, 86, 214);    
    }

    .correction a {
      color: rgb(0, 86, 214);
      text-decoration: none;
      font-weight: normal;
    }

  </style>
</head>
<body>

  <div class="header">
    CORRESPONDENCE
    <span class="label">| Nov 13, 2024 | <span class="free">FREE</span></span>
  </div>

  <div class="image">
    <img src="images/chart.png" alt="" />
  </div>

  <h1>Activity of Research-Grade Pemivibart against SARS-CoV-2 Sublineages</h1>
  <h2>Q. Wang and Others</h2>

  <p class="article-body">
    SARS-CoV-2 continues to evolve under immunologic pressure. A
    synthesized version of pemivibart, an antiâ€“SARS-CoV-2 monoclonal
    antibody with recent emergency-use authorization, showed mixed
    activity against emerging variants.
  </p>

  <p class="correction">
  <strong>Correction</strong>
  <a href="#">Pemivibart Activity against Recent SARS-CoV-2 JN.1
    Sublineages</a>
</p>

</body>
</html>